Godavari Drugs Ltd Fair Value
GODAVARI · Healthcare · Current price ₹105.5
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹69 | 10% ROE fading to 13% over ~3 yrs, on ₹71 book |
| Relative P/E | ₹226 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹109 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Godavari Drugs Ltd undervalued?
DocStoX estimates the fair value of Godavari Drugs Ltd at ₹119 per share, versus the current market price of ₹106. That puts the stock about +13.2% below our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹69), Relative P/E (₹226), Graham floor (₹109). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹69 (bear) to ₹119 (base) to ₹226 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Godavari Drugs Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.